Inactive Instrument

Fuss Brands Corp.

FBDS

US16890Y1047

Fuss Brands Corp. announced that it has received $0.078 million in funding

January 17, 2023

On January 18, 2023, Fuss Brands Corp. closed the transaction. The company amended the terms of the transaction.The company has raised additional $75,500 in its second and final tranche closing.

The company has raised a total of $78,000 from 5 investors in the transaction.

Latest news about Fuss Brands Corp.

Fuss Brands Corp. Reports Earnings Results for the First Quarter Ended January 31, 2024	03-18	CI
Fuss Brands Corp. Reports Earnings Results for the Full Year Ended October 31, 2023	02-05	CI
Fuss Brands Corp. Announces Resignation of Issamar Ginzberg as Chief Executive Officer	01-11	CI
Fuss Brands Corp. Announces Board Changes	01-11	CI
Fuss Brands Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2023	23-09-05	CI
Fuss Brands Corp. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2023	23-06-12	CI
Fuss Brands Corp. Reports Earnings Results for the First Quarter Ended January 31, 2023	23-03-09	CI
Fuss Brands Corp. Reports Earnings Results for the Full Year Ended October 31, 2022	23-01-27	CI
Fuss Brands Corp. Receives Purchase Order from Roomwagon, LLC	23-01-27	CI
Fuss Brands Corp. Auditor Raises 'Going Concern' Doubt	23-01-26	CI
Fuss Brands Corp. announced that it has received $0.078 million in funding	23-01-17	CI
Fuss Brands Corp. Signs Licensing Agreement with Anyvention Ltd. to Acquire Intellectual Property Rights	22-11-04	CI
Fuss Brands Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2022	22-09-08	CI
China Botanic Pharmaceuticals Inc. has Changed its Name to Fuss Brands Corp	22-07-22	CI
China Botanic Pharmaceutical Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2022	22-06-08	CI
Fuss Brands Corp. announced a financing transaction	22-06-03	CI
China Botanic Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended January 31, 2022	22-02-25	CI
China Botanic Pharmaceutical Inc. Auditor Raises 'Going Concern' Doubt	21-12-15	CI
China Botanic Pharmaceutical Inc. Announces Management Changes	21-08-25	CI
China Botanic Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended January 31, 2021	21-07-14	CI
China Botanic Pharmaceutical Inc. Announces Executive Appointments	21-02-17	CI
China Botanic Pharmaceutical Inc. Appoints David Lazar as Chief Executive Officer	21-02-17	CI
China Botanic Pharmaceutical Inc. Appoints David Lazar as Chief Financial Officer	21-02-17	CI
China Botanic Pharmaceutical Inc. Appoints Jack Zhao as Independent Director, Chairman of the Audit Committee, and Member of Compensation Committee and Nomination Committee	13-01-23	CI
Zack Pan Resigns as Chair of the Audit Committee, Member of the Compensation Committee and the Nominations Committee, and as Director of China Botanic Pharmaceutical Inc., Effective December 24, 2012	12-12-28	CI

Fuss Brands Corp. is a shell company. The Company intends to explore and identify business opportunities within the United States, including an acquisition of an operating entity through a reverse merger, asset purchase, or similar transaction. The Company has no operations and has not generated any revenue.

Sector

More about the company

Fuss Brands Corp.

Equities

FBDS

US16890Y1047

Fuss Brands Corp. announced that it has received $0.078 million in funding

Latest news about Fuss Brands Corp.

Chart Fuss Brands Corp.

Company Profile